The appointment adds biopharma governance and investment expertise to the board. Traders should monitor for potential strategic shifts given Dr. Doux’s background in rare disease therapeutics and prior board experience, though no immediate changes are indicated.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $129.00entry
- T+1 · 7mo ago +0.41%α −0.80% · $129.53
- T+5 · 7mo ago +0.26%α −3.04% · $129.33
- T+20 · 6mo ago −5.36%α −13.08% · $122.09
- T+60 · 4mo ago +12.55%α +3.63% · $145.19
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Palvella Therapeutics appointed John Doux, M.D., to its Board of Directors as a Class III member, effective April 13, 2026. Dr. Doux brings extensive experience in dermatology, biotech investing, and corporate governance from prior board roles in healthcare companies.
Key Facts
- John Doux, M.D., was appointed to the Board of Directors effective April 13, 2026
- Board size increased from six to seven members
- Dr. Doux is a board-certified dermatologist and healthcare investor at Palo Alto Investors LP
- He previously served on Palvella's board from 2019 to 2022 prior to its reverse merger
- No departures or executive officer changes announced
- Dr. Doux received an option grant to purchase 6,000 shares, vesting monthly over 36 months
Financial Impact
Minimal near-term financial impact; option grant for 6,000 shares represents minor potential dilution
Risk Factors
- Minimal execution risk as this is a board expansion, not a C-suite change
- Potential for increased investor scrutiny due to Dr. Doux’s analytical background
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-151979 |
| Document: 0001193125-26-151979-index-headers.html | 0001193125-26-151979 |
| Document: 0001193125-26-151979-index.html | 0001193125-26-151979 |
| Document: 0001193125-26-151979.txt | 0001193125-26-151979 |
Track record
36 reports on PVLA
4 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +35.07% at T+60 after the May 15, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $145.21 Now $144.60 −0.42% settles Dec 16
- Nov 10, 20266d ago 144 Neutral 5/10 Entry $163.94 Now $144.60 −11.80% settles Dec 10
- Nov 5, 202611d ago 8-K Bullish 7/10 Entry $156.85 Now $144.60 −7.81% settles Dec 4
- Nov 5, 202611d ago Press Release Neutral 6/10 No price data
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $152.93 Now $144.60 −5.45% settles Dec 2
- Oct 28, 202619d ago SC 13G/A Neutral 3/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago 8-K Bullish 6/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 28, 202619d ago Press Release Bullish 7/10 Entry $147.47 Now $144.60 −1.95% settles Nov 25
- Oct 23, 202624d ago Insider Cluster Neutral 2/10 Entry $126.23 Now $144.60 +14.55% settles Nov 23
- Oct 15, 20264w ago Press Release Neutral 4/10 Entry $127.34 to $153.18 Now $144.60 +13.55% ▲ +20.29% +22.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers